Stereotaxis, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $6,482 thousand for the third quarter.

Key Highlights

  • Q3 2026 total revenue: $8,925 thousand, up from $7,464 thousand in Q3 2025, according to the filing.
  • Q3 2026 net loss: $6,482 thousand, compared to a net loss of $6,463 thousand in Q3 2025, the company reported.
  • Nine-month net loss: $16,811 thousand for the nine months ended September 30, 2026, versus $16,112 thousand for the same period in 2025.
  • Goodwill increased sharply: Goodwill rose to $29,276 thousand at September 30, 2026, from $3,764 thousand at December 31, 2025, reflecting the Robocath acquisition disclosed in the filing.
  • Cash position declined: Cash and cash equivalents stood at $3,976 thousand at September 30, 2026, down from $13,421 thousand at December 31, 2025.
  • Common shares outstanding: 100,855,732 shares as of October 31, 2026, compared to 95,339,628 shares issued at December 31, 2025.
  • Accumulated deficit: $600,179 thousand at September 30, 2026, up from $583,368 thousand at December 31, 2025.

Stereotaxis Q3 2026 Results: Revenue Growth, Robocath Acquisition, and Continued Losses

Stereotaxis, Inc. (NYSE American:STXS), a Delaware-incorporated medical device company headquartered in St. Louis, Missouri, reported its unaudited consolidated financial results for the three and nine months ended September 30, 2026. According to the filing, total revenue for the third quarter reached $8,925 thousand, an increase from $7,464 thousand in the prior-year quarter. Systems revenue was $2,976 thousand in Q3 2026 versus $1,861 thousand in Q3 2025, while disposables, service and accessories revenue was $5,949 thousand compared to $5,603 thousand in the year-ago period.

The company reported a gross margin of $3,956 thousand for Q3 2026, down from $4,101 thousand in Q3 2025, as total cost of revenue rose to $4,969 thousand from $3,363 thousand. Total operating expenses were $10,427 thousand in Q3 2026 versus $10,658 thousand in Q3 2025, resulting in an operating loss of $6,471 thousand for the quarter. Net loss per share attributable to common stockholders was $(0.07) basic and diluted for both Q3 2026 and Q3 2025, the filing stated.

The balance sheet reflected significant changes from year-end 2025, which the filing attributes in part to the Robocath acquisition. Goodwill grew to $29,276 thousand from $3,764 thousand, and the company issued stock and warrants in connection with that acquisition valued at $13,346 thousand during the three months ended September 30, 2026. Total assets increased to $82,112 thousand at September 30, 2026, from $52,251 thousand at December 31, 2025. Long-term contingent consideration also rose to $14,928 thousand from $4,724 thousand. The company carried $1,922 thousand in long-term debt at the end of the quarter, compared to none at year-end 2025. Insurance receivable and accrued legal liabilities each stood at $9,982 thousand at September 30, 2026.

What Was Disclosed

Stereotaxis filed its quarterly report covering the period ended September 30, 2026, disclosing revenue of $8,925 thousand, a net loss of $6,482 thousand, a significantly expanded balance sheet following the Robocath acquisition, and cash of $3,976 thousand at quarter-end.